Alex W Jacobitz

Title: Innovations of Alex W Jacobitz in Biopharmaceuticals

Introduction

Alex W Jacobitz is a notable inventor based in Thousand Oaks, CA (US). He has made significant contributions to the field of biopharmaceuticals, particularly in the development of bispecific antibodies. His work is characterized by innovative approaches that enhance the efficacy of therapeutic molecules.

Latest Patents

Jacobitz holds a patent for "Bispecific antibodies with cleavable C-terminal charge-paired tags." This invention involves a CH3-containing molecule that comprises a first polypeptide with a CH3 domain and a negatively charged domain, as well as a second polypeptide with a CH3 domain and a positively charged domain. The patent outlines methods for conjugating synthetic molecules to a multi-specific antigen binding molecule, showcasing his expertise in antibody engineering.

Career Highlights

Jacobitz is currently employed at Amgen Inc., a leading biotechnology company known for its innovative therapies. His role at Amgen allows him to work on cutting-edge research and development projects that aim to improve patient outcomes through advanced biopharmaceutical solutions.

Collaborations

Throughout his career, Jacobitz has collaborated with esteemed colleagues, including John K Kawooya and Christopher Mohr. These collaborations have fostered a dynamic environment for innovation and have contributed to the advancement of biopharmaceutical technologies.

Conclusion

Alex W Jacobitz is a prominent figure in the field of biopharmaceuticals, with a focus on bispecific antibodies. His patent and work at Amgen Inc. reflect his commitment to advancing medical science and improving therapeutic options for patients.